The "Cocaine Use Disorder Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering.

The Cocaine Use Disorder Market is experiencing substantial growth, expanding from USD 1.29 billion in 2024 to USD 1.36 billion in 2025, with projections indicating a CAGR of 5.82% reaching USD 2.03 billion by 2032. This comprehensive market research study sheds light on the evolving dynamics and strategic imperatives within the cocaine use disorder treatment landscape. The report provides essential insights for stakeholders navigating the complexities of treatment modalities, regulatory shifts, and external forces affecting patient outcomes since the late twentieth century.

Transformative Shifts in Treatment Innovation

Recent advances in neurobiological research and digital therapeutics have catalyzed a paradigm shift in treating cocaine use disorder, emphasizing personalized medicine and innovative care models. Regulatory agencies have adopted more adaptive frameworks, enabling expedited implementation of novel therapies. For decision-makers, these advancements present opportunities for strategic planning and capturing competitive advantages through emerging technologies.

Telehealth platforms and mobile solutions have further expanded the reach of behavioral therapies, generating real-world data to refine treatment algorithms. Such integrative approaches underscore the market's progression toward sustainable outcomes.

Key Takeaways from This Report

• Identifies high-impact opportunities for decision-makers within the cocaine use disorder treatment market.
• Offers insights into emerging trends and innovative care models driving sustainable patient outcomes.
• Highlights the importance of strategic partnerships and regional diversification in mitigating tariff impacts.
• Provides direction for leveraging supply chain resilience and data-driven execution in market strategies.

Market Segmentation & Coverage

The report forecasts revenues and analyzes trends in segmentation by treatment modality, setting, indication, diagnostic testing, payer type, provider network, and regional dynamics. The following detailed breakdowns are examined:

• Treatment Modality
  • Behavioral Therapy
    • Cognitive Behavioral Therapy
    • Contingency Management
    • Motivational Interviewing
  • Combined Therapy
    • Integrated Programs
    • Sequential Programs
  • Pharmacotherapy
    • Antidepressants
      • Selective Serotonin Reuptake Inhibitors
      • Serotonin-Norepinephrine Reuptake Inhibitors
    • Psychostimulants
• Treatment Setting
  • Inpatient
    • Detoxification
    • Residential Rehabilitation
  • Outpatient
• Indication
  • Acute
  • Chronic
• Diagnostic Tests
  • Cardiovascular Examination
  • Neurologic Examination
  • Urine Toxicology Examination

Key Attributes

The companies profiled in this Cocaine Use Disorder market report include:

• Alkermes PLC
• Alnylam Pharmaceuticals, Inc.
• Camurus AB
• Embera NeuroTherapeutics, Inc.
• Indivior PLC
• Johnson & Johnson Services, Inc.
• KemPharm, Inc.
• Kinoxis Therapeutics
• Novartis International AG
• Orexo AB
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Polpharma SA
• Revive Therapeutics Ltd.
• Sage Therapeutics, Inc.
• Saniona AB
• Shionogi & Co., Ltd.
• Sigmapharm Laboratories, LLC
• STALICLA SA
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc.
• Mylan Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/mg5h70

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251210769983/en/